The Role of Nanomaterials and Biological Agents on Rotator Cuff Regeneration.

The rotator cuff is a musculotendon unit responsible for movement in the shoulder. Rotator cuff tears represent a significant number of musculoskeletal injuries in the adult population. In addition, there is a high incidence of retear rates due to various complications within the complex anatomical structure and the lack of proper healing.

Reduced Platelet Adhesion for Blended Electrospun Meshes with Low Amounts of Collagen Type I.

A clinically approved, tissue engineered graft is needed as an alternative for small-diameter artery replacement. Collagen type I is commonly investigated for naturally derived grafts. However, collagen promotes thrombosis, currently requiring a graft pre-seeding step.

Regenerative engineering: a review of recent advances and future directions.

Regenerative engineering is defined as the convergence of the disciplines of advanced material science, stem cell science, physics, developmental biology and clinical translation for the regeneration of complex tissues and organ systems. It is an expansion of tissue engineering, which was first developed as a method of repair and restoration of human tissue. In the past three decades, advances in regenerative engineering have made it possible to treat a variety of clinical challenges by utilizing cutting-edge technology currently available to harness the body's healing and regenerative abilities.

Poly(butyl cyanoacrylate) nanoparticle containing an organic photoCORM.

Carbon monoxide (CO) is a gasotransmitter, which has shown therapeutic effects in recent studies. Photo carbon monoxide releasing molecules (PhotoCORMs) allow the delivery of CO to be controlled by light. In this work, a new organic photoCORM DK4 is studied.

Delivery of Antioxidant and Anti-inflammatory Agents for Tissue Engineered Vascular Grafts.

The treatment of patients with severe coronary and peripheral artery disease represents a significant clinical need, especially for those patients that require a bypass graft and do not have viable veins for autologous grafting. Tissue engineering is being investigated to generate an alternative graft. While tissue engineering requires surgical intervention, the release of pharmacological agents is also an important part of many tissue engineering strategies.